COMBinATion nivolumab and decitabine for treatment of primary GlioBlastoma (COMBAT-GB)

Research summary

To assess the safety and tolerability of neoadjuvant ASTX727 (decitabine and cedazuridine) and Nivolumab combination therapy and determine the maximum tolerated dose combination (the dose associated with no more than 25% dose limiting toxicity (DLT) rate).

Principal Investigator

Dr Meera Nandhabalan

Contact us

Email: orh-tr.earlyphasenurses@nhs.net

IRAS number

1007984